These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 17067184)

  • 1. Management of Parkinson's disease dementia : practical considerations.
    Rongve A; Aarsland D
    Drugs Aging; 2006; 23(10):807-22. PubMed ID: 17067184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
    Szeto JY; Lewis SJ
    Curr Neuropharmacol; 2016; 14(4):326-38. PubMed ID: 26644155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
    Wang HF; Yu JT; Tang SW; Jiang T; Tan CC; Meng XF; Wang C; Tan MS; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):135-43. PubMed ID: 24828899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lewy body dementia and Parkinson disease dementia].
    Meyniel C; Damier P
    Presse Med; 2007 Oct; 36(10 Pt 2):1485-90. PubMed ID: 17572053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia--common features and differences].
    Drach LM
    Med Monatsschr Pharm; 2011 Feb; 34(2):47-52; quiz 53-4. PubMed ID: 21428015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
    Zahodne LB; Fernandez HH
    Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When a Parkinson's disease patient starts to hallucinate.
    Poewe W
    Pract Neurol; 2008 Aug; 8(4):238-41. PubMed ID: 18644910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.
    Burton EJ; McKeith IG; Burn DJ; Williams ED; O'Brien JT
    Brain; 2004 Apr; 127(Pt 4):791-800. PubMed ID: 14749292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia.
    Piggott MA; Ballard CG; Dickinson HO; McKeith IG; Perry RH; Perry EK
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):231-44. PubMed ID: 16448581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosis in nursing home patients with Parkinson's disease.
    Kang GA; Bronstein JM
    J Am Med Dir Assoc; 2004; 5(3):167-73. PubMed ID: 15115577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
    Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
    Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
    Scheepmaker AJ; Horstink MW; Hoefnagels WH; Strijks FE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(1):32-5. PubMed ID: 12564296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global cognitive performance is associated with sleep efficiency measured by polysomnography in patients with Parkinson's disease.
    Sobreira EST; Sobreira-Neto MA; Pena-Pereira MA; Chagas MHN; Fernandes RMF; Eckeli AL; Tumas V
    Psychiatry Clin Neurosci; 2019 May; 73(5):248-253. PubMed ID: 30636105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and management of Parkinson's disease dementia.
    Poewe W; Gauthier S; Aarsland D; Leverenz JB; Barone P; Weintraub D; Tolosa E; Dubois B
    Int J Clin Pract; 2008 Oct; 62(10):1581-7. PubMed ID: 18822028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive impairment and dementia in Parkinson's disease: practical issues and management.
    Emre M; Ford PJ; Bilgiç B; Uç EY
    Mov Disord; 2014 Apr; 29(5):663-72. PubMed ID: 24757114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review.
    Leroi I; Collins D; Marsh L
    J Neurol Sci; 2006 Oct; 248(1-2):104-14. PubMed ID: 16806271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine and Parkinson dementia complex.
    Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G
    Expert Opin Pharmacother; 2007 Apr; 8(6):817-29. PubMed ID: 17425477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosis in Parkinson's disease.
    Poewe W
    Mov Disord; 2003 Sep; 18 Suppl 6():S80-7. PubMed ID: 14502660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia.
    Borroni B; Premi E; Formenti A; Turrone R; Alberici A; Cottini E; Rizzetti C; Gasparotti R; Padovani A
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1049-55. PubMed ID: 26109553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
    Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
    Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.